Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition

15 Nov 2019

Abstract excerpt

Janus kinase (JAK) inhibitors have emerged as an effective class of therapies for various inflammatory diseases such as rheumatoid arthritis (RA). JAK inhibitors function intracellularly by modulating the catalytic activity of JAKs and disrupting the receptor-mediated signaling of multiple cytokines and growth factors, including those with pro-inflammatory activity. Understanding the inhibition profiles of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytokine Signaling Pathways and Interactions
Share to HER2/EGFR in Cancer Research
Share to Rheumatoid Arthritis Research and Therapies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31832202
DOI: 10.1002/prp2.537

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibitionPMID 31832202Read ↗

Upadacitinib: Mechanism of action, clinical, and translational scienceSemantic proximity Read ↗

Synovial fibroblast niche shapes the efficacy–safety dynamics of JAK inhibition in rheumatoid arthritisSemantic proximity Read ↗

A Computational Modeling Framework to Analyze Synovial-Tissue Based Drug Targets and Diagnostic Biomarkers in Rheumatoid ArthritisSemantic proximity Read ↗

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritisSemantic proximity Read ↗

Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseasesSemantic proximity Read ↗

JAK Kinases in Health and Disease: An UpdateSemantic proximity Read ↗

JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016–present)Semantic proximity Read ↗

Modern Pharmacologic Management of Rheumatoid Arthritis: From Methotrexate to Targeted TherapiesSemantic proximity Read ↗

Current application status and structure–activity relationship of selective and non-selective JAK inhibitors in diseasesSemantic proximity Read ↗

Safety of JAK and IL-6 inhibitors in rheumatoid arthritis: a multicentor cohort studySemantic proximity Read ↗

Molecular Structure and Function of Janus Kinases: Implications for the Development of InhibitorsSemantic proximity Read ↗

JAK selectivity: more precision less troublesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.